Dr. Reddy's announces the launch of Fosaprepitant for Injection in US market

Dr. Reddy’s Laboratories has announced the launch of Fosaprepitant for Injection, the therapeutic generic equivalent of EMEND® (fosaprepitant) for injection, approved by the USFDA.

Marc Kikuchi, Chief Executive Officer, North America Generics, Dr. Reddy’s Laboratories said, “We are pleased to be among the first generics to launch this product. This is a great addition to our injectable portfolio in the U.S. market as we continue to augment our product offering and drive growth for the hospital segment.”

The EMEND® for Injection brand had an U.S. sales of approximately $279 million MAT for the most recent twelve months ending in July 2019 according to IQVIA Health.

Dr. Reddy’s Fosaprepitant for Injection is available in 150 mg single-dose vial for reconstitution.